Antiagregación plaquetaria: stents, isquemia y sangrado ¿Qué sabemos al respecto? / Platelet antiaggregation: stents, ischemia and bleeding What do we know about it?
Rev. méd. Maule
;
37(1): 105-113, jun. 2022. tab, ilus
Article
in Spanish
| LILACS
| ID: biblio-1397776
ABSTRACT
Antiplatelet therapy and percutaneous coronary intervention are two of the most important interventions in the management of coronary artery disease. In the last 20 years there has been groundbreaking advances in the pharmacotherapy and stent technology. Bleeding is the most feared complication of antiplatelet therapy, mainly due to the increase in major adverse cardiovascular events besides the bleeding itself. Different clinical decision tools have developed with the aim to define which patients have a high ischemic or bleeding risk, thus individualizing treatment.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Platelet Aggregation Inhibitors
/
Drug Therapy, Combination
/
Percutaneous Coronary Intervention
Type of study:
Prognostic study
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Maule
Journal subject:
Medicine
Year:
2022
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Hospital Regional de Talca/CL
/
Universidad Católica del Maule/CL
Similar
MEDLINE
...
LILACS
LIS